[Skip to the reading](https://peptidesandprosecco.com/bpc-157-and-ghk-cu#reading) 

[Peptides and Prosecco](/) 

[What did my friend mean?](/#what-i-heard) 
[What are GLP-1 medicines?](/glp-1-medicines) 
[What would I ask a clinician?](/care-questions) 

[Home](/) / BPC-157 and GHK-Cu

# Keep recovery stories and skin research in separate seats

BPC-157 comes up in recovery talk; GHK-Cu comes up in skin care. I’d keep the two conversations separate. Neither has an FDA-approved medicine, and an interesting finding doesn’t tell us that a treatment works for the person hearing about it.

## BPC-157 has a human-evidence gap

![A relaxed bare ankle rests on a mineral-grey footstool beside a sunlit chair.](/prosecco-stoop-67c4ce88067d/resting-ankle.webp)

A recovery story can be a starting question without becoming proof.

BPC-157 is assembled in the lab from amino acids. Those are protein’s building blocks, joined here as a short chain. Most recovery research involves cells or animals. A [review of muscle and joint research found very little human evidence](https://pubmed.ncbi.nlm.nih.gov/40789979/) . That leaves a big gap when someone asks whether it will help their injury.

I can believe a friend feels better without knowing why. What was the injury? What other care were they getting? Those questions help me understand the story without turning their experience into proof for everyone else.

[FDA found too little clinical safety information](https://www.fda.gov/media/193343/download) to describe BPC-157’s risks reliably. The human studies were small and short, with limited safety monitoring. There’s no FDA-approved label covering interactions or pregnancy risks, either. Missing information leaves uncertainty about harm.

## GHK-Cu brings copper into the skin conversation

![A softly folded strip of copper catches daylight on a pale mineral surface.](/prosecco-stoop-67c4ce88067d/copper-fold.webp)

The Cu in GHK-Cu means copper; the route still matters.

GHK-Cu is a peptide made of three protein building blocks, bound to copper. You may hear about it in creams and serums. A [review of topical GHK found a shortage of studies in people](https://pubmed.ncbi.nlm.nih.gov/39963574/) , so the evidence in people is much thinner than the confident skin claims might suggest.

A skin product and an injection need separate evidence. [FDA flags limited human safety data for injectable GHK-Cu](https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks) and worries about immune reactions from clumping or impurities. Those concerns are about injected preparations; they don’t establish the same harms from a cream.

## Withdrawal leaves the safety question open

On FDA’s compounding safety page current as of April 22, 2026, BPC-157 and injectable GHK-Cu are listed as nominated but withdrawn. The requests were to add ingredients to the 503A list used in pharmacy compounding, or making medicines for particular patient needs. The groups behind those requests pulled them back. FDA’s safety concerns remain; withdrawal isn’t clearance.

## Bring the underlying concern to care

For an injury or skin concern, I’d bring the problem itself to a licensed U.S. clinician, along with the name I’d heard. Ask what established options fit and what evidence would support anything else. Non-injectable GHK-Cu has a separate compounding status from the injectable form. A research-use label isn’t a way to settle a personal treatment decision.

[ Questions for an appointment](/care-questions) [ See the sources](/references) 

I keep this a guide for the questions that linger; it is not a clinic, pharmacy or seller.

[BPC-157 and GHK-Cu](/bpc-157-and-ghk-cu) [NAD+ and PT-141](/nad-and-pt-141) [References](/references) [About](/about) [Contact](/contact) 

© 2026 Peptides and Prosecco